<DOC>
	<DOCNO>NCT00035945</DOCNO>
	<brief_summary>Purpose study evaluate safety , tolerability , antiviral activity , pharmacokinetic behavior ISIS 14803 administer 12 week intravenous infusion patient chronic hepatitis C .</brief_summary>
	<brief_title>ISIS 14803-CS2 , Treatment With ISIS 14803 , Administered IV Patients With Chronic Hepatitis C Virus Infections</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Inclusion Criteria Patients must meet follow inclusion criterion screen : Age great equal 18 year . Both male female eligible . All patient advise data possible reproductive ( teratological ) effect ISIS 14803 . Therefore : ) Females may participate surgically sterile postmenopausal . Premenopausal woman may participate abstinent compliant contraceptive regimen . Abstinence contraceptive regimen must maintain treatment period 4 week discontinuation therapy . A negative serum pregnancy test ( i.e. , human chorionic gonadotropin , hCG ) within 2 week prior dose ISIS 14803 require premenopausal woman . Subjects must breast feeding . b ) Male patient must surgically sterile , abstinent , utilize barrier contraceptive method . Abstinence contraceptive regimen must maintain treatment period 4 week discontinuation therapy . AntiHCV antibody positive . Plasma HCV RNA great 10,000 copies/mL . Prior liver biopsy indicate chronic hepatitis . WBC count less equal upper limit normal . Absolute neutrophil count normal range laboratory . Platelet count great 130,000 cells/mmÂ³ . Hemoglobin concentration great equal 11 g/dL . PT normal range laboratory . Normal aPTT . Bilirubin normal range unless due document Gilbert 's disease . Serum creatinine less equal 1.5 time upper limit normal range . Urinalysis show evidence infection active renal disease ( e.g. , proteinuria ) . Subjects must able adhere visit schedule set forth protocol . Written inform consent prior performance study related procedure . Patients follow criterion screen eligible : Human immunodeficiency virus ( HIV ) infection ( Western immunoblot confirm presence antiHIV antibody detection HIV RNA blood ) . Chronic hepatitis B virus ( HBV ) infection ( HBV surface antigen DNA blood ) . Antiviral therapy HCV within 3 month . Immunomodulatory therapy ( e.g. , systemic corticosteriods interferon ) within 3 month . Advanced decompensated liver disease ( e.g. , history bleeding varix , spontaneous hepatic encephalopathy , ascites ) etiology alcohol , drug , obesity , hemochromatosis . ALT great 5x ULN . Histologic evidence cirrhosis . Presence underlying disease state associate active bleeding . Undergoing therapeutic anticoagulation heparin warfarin . Presence active infection require therapy . Presence malignancy . Presence history significant medical illness might interfere study . Receipt investigational new drug , biological therapeutic device within 30 day study entry . Alcohol drug abuse require medical intervention within 2 year . History noncompliance prescribe medical care . Limited mental capacity language skill extent simple instruction follow information regard adverse event provide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>